



University of Kentucky
UKnowledge

Markey Cancer Center Faculty Publications

Cancer

5-31-2017

Potent Anti-Cancer Effects of Less Polar Curcumin Analogues on Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Cells

Fatemeh Alibeiki

Ardabil University of Medical Science, Iran

Naser Jafari

University of Kentucky, naser.jafari@uky.edu

Maryam Karimi

Tehran University of Medical Science, Iran

Hadi Peeri Dogahneh

Ardabil University of Medical Science, Iran

[Click here to let us know how access to this document benefits you.](#)

Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub

 Part of the [Chemicals and Drugs Commons](#), [Diseases Commons](#), and the [Oncology Commons](#)

Repository Citation

Alibeiki, Fatemeh; Jafari, Naser; Karimi, Maryam; and Peeri Dogahneh, Hadi, "Potent Anti-Cancer Effects of Less Polar Curcumin Analogues on Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Cells" (2017). *Markey Cancer Center Faculty Publications*. 94.

https://uknowledge.uky.edu/markey_facpub/94

This Article is brought to you for free and open access by the Cancer at UKnowledge. It has been accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Potent Anti-Cancer Effects of Less Polar Curcumin Analogues on Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Cells

Notes/Citation Information

Published in *Scientific Reports*, v. 7, article no. 2559, p. 1-9.

© The Author(s) 2017

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Digital Object Identifier (DOI)

<https://doi.org/10.1038/s41598-017-02666-4>

SCIENTIFIC REPORTS



OPEN

Potent anti-cancer effects of less polar Curcumin analogues on gastric adenocarcinoma and esophageal squamous cell carcinoma cells

Fatemeh Alibeiki¹, Naser Jafari^{1,2}, Maryam Karimi³ & Hadi Peeri Dogaheh¹

Curcumin and its chalcone derivatives inhibit the growth of human cancer cells. It is reported that replacement of two OH groups in curcumin with less polar groups like methoxy increases its anti-proliferative activity. In this study, we explored benzylidene cyclohexanone derivatives with non-polar groups, to see if they possess increased anti-cancer activity. Novel 2,6-bis benzylidene cyclohexanone analogues of curcumin were synthesized, and their inhibitory effects on gastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cancer cells were studied using an MTT assay. Cell apoptosis was detected by EB/AO staining, and cell cycle was analyzed by flow cytometry. Real-time PCR was performed for gene expression analysis. All synthesized analogues were cytotoxic toward gastric and esophageal cancer cells and showed lower IC₅₀ values than curcumin. Treatment with 2,6-Bis-(3-methoxy-4-propoxy-benzylidene)-cyclohexanone (BM2) was 17 times more toxic than curcumin after 48 h incubation. All novel compounds were more effective than curcumin in apoptosis induction and cell cycle arrest at G1 phase. These results suggest that less polar analogues of curcumin have potent cytotoxicity *in vitro*. However, they need to be investigated further, especially with animal tumor models, to confirm their chemotherapeutic activity *in vivo*.

Curcumin is the most active component of rhizomes of *Curcuma longa* L. (also known as turmeric) and is classified in the family Zingiberaceae. It has been studied extensively due to its bio-functional properties, especially antioxidant, anticancer, anti-growth, antiarthritic, antiatherosclerotic, antidepressant, antiaging, antidiabetic, antimicrobial and anti-inflammatory activities¹.

These activities have been attributed to methoxy, hydroxyl, α , β -unsaturated carbonyl moiety, or diketone groups in curcumin².

Curcumin's key mechanisms of chemotherapeutic action include inducing apoptosis; inhibiting proliferation, migration and invasion of tumors; and also weakening tumors to radiotherapy and chemotherapy. At a molecular level, this multi-targeted agent has been shown to exhibit anti-inflammatory activity through suppression of numerous cell signaling pathways including NF- κ B, STAT3, NRF2, ROS, and COX2³.

Several studies reported curcumin's anti-cancer effects on gastrointestinal cancers, leukemia, breast cancer, genitourinary cancers, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, neurological cancers, and sarcoma⁴, which demonstrate its potential capability to affect multiple targets.

Despite all these facts, the utility of curcumin is limited by its low bioavailability⁴. Thus, modifications of specific functional groups of curcumin that increase its bioavailability will increase its activity. Developing structural analogues of curcumin and synthesis of "man-made" curcumin analogues plays a role in the improvement of its bioavailability. For instance, the natural analogues of curcumin such as dimethoxy-curcumin and bidehydroxy-curcumin were reported to have similar biological activity to curcumin⁵. Moreover, it has been

¹School of Medicine, Ardabil University of Medical Science, Ardabil, 56197, Iran. ²Markey Cancer Center, University of Kentucky, Lexington, KY, USA. ³Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Science, Tehran, 14176, Iran. Correspondence and requests for materials should be addressed to N.J. (email: naser.jafari@uky.edu)




Figure 1. Synthesized primary aromatic aldehydes.

reported that chalcone and bis-chalcone derivatives have inhibited the growth of the human breast and colon cancer cell lines⁶.

In this study, our purpose was to explore efficacy of benzylidene cyclohexanone derivatives with methoxy, ethoxy, alkoxy, and propoxy groups, to see if they possess increased anti-cancer activity and to explore the mechanism of action of these analogues. In order to accomplish this, we developed a new series of 2,6-bis benzylidene cyclohexanone derivatives that indicate increased activity against gastric and esophageal cancer cells *in vitro*, compared to treatment with unmodified curcumin.

Methods

Synthesis of 2,6-bis benzylidene cyclohexanone derivatives. Benzaldehydes including 4-hydroxybenzaldehyde and 4-hydroxyl, 3-Methoxy benzaldehyde (5 mM) were dissolved in 25 mL solution of N,N-Dimethylformamide (DMF) including potassium carbonate (K_2CO_3 , 6 mM) as a catalytic base for 1 h at 80 °C. Afterward, individual reactions received one of the propargyl bromide, allyl bromide, or iodoethane. Then mixtures were heated and mixed for 24 h.

In order to extract benzaldehydes from DMF, 100 mL water and 50 mL ethyl acetate were added to mixtures and organic phases were isolated. Then compounds were dried on sodium sulfate, and finally ethyl acetate was evaporated.

Thin-layer chromatography (TLC) was conducted to determine the purity of products. The selected aromatic aldehydes were as follows: 4-propoxy benzaldehyde (3a), 3-methoxy, 4-propoxy benzaldehyde (3b), 4-Alkoxy, 3-Methoxy benzaldehyde (3c), 4-ethoxy, and 3-methoxy benzaldehyde (3d) (Fig. 1).

2,6-bis benzylidene cyclohexanones (4a – 4e) were prepared by reacting 2 equivalents of aromatic aldehydes with 1 equivalent of cyclohexanone in the presence of ethanol and hydrochloric acid gas. Then the compounds were washed with cold ethanol and verified by TLC (Fig. 2). Finally, products were characterized and analyzed by ^{13}C -NMR, 1H -NMR and FT-IR.

Details of generated 2,6-bis benzylidene cyclohexanones including formula, structure, molecular weight, melting point, color and yield are presented in Table 1.

Cell Culture and Treatment. The human gastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cell lines were provided by the Pasteur Institute of Iran. All reagents, chemicals and media were prepared and used freshly.

Cancer cells were grown in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS), penicillin (100 unit/ml) and streptomycin (100 μ g/ml). Cells were cultured at 37 °C in a moistened atmosphere of 5% CO_2 and 95% air. Then, cells were trypsinized and plated in 96-well plates at a density of 1×10^4 cells per well in 150 μ l medium, and incubated overnight. Next, cells were treated with a FBS-free medium containing 1 mg/ml of each compound by 1/4 serial dilutions. Then, plates were incubated for 24, 48, and 72 h. The cytotoxicity of curcumin derivatives was determined by an MTT assay.

MTT Assay. Culture media were removed 4 h before completion of the incubation time, then 200 μ l of 0.25 mg/ml MTT (Merck, Germany) was added to each well. Plates were incubated again for an additional 4 h in order to complete the incubation time. The supernatants were removed and 200 μ l DMSO was added to the wells, and the plates were shaken for 10 min. The absorbance was measured at 540 nm by a plate reader (Synergy HT, BioTek).

Apoptotic Cell detection by EB/AO Staining. Cells were cultured in 96-well plates at a confluence of 1×10^3 cells/well, incubated overnight and then treated with compounds in their 24 h specific IC_{50} doses. Then plates were centrifuged for 5 min (129 g, 1,000 rpm) at 4 °C. The ethidium bromide/acridine orange (EB/AO) dye mix (100 μ g/ml ethidium bromide and 100 μ g/ml acridine orange) was dissolved in PBS and 20 μ l of the dye mix was added to wells. Cells were counted by an inverted fluorescence microscope (IX 71, OLYMPUS). Live cells




Figure 2. Synthesized 2,6-bis benzylidene cyclohexanones (4a – 4e also named BM1- BM5).

were determined by normal green color, which resulted from up-taking acridine orange (green fluorescence) and repelling ethidium bromide (red fluorescence).

Apoptotic cells display apoptotic bodies and perinuclear condensation of chromatin stained by ethidium bromide, while live cells were identified as normal nuclear chromatin stained by acridine orange. Necrotic cells were detected by uniform ethidium bromide staining of the cells⁷. Images were captured with a digital camera (DP 71, OLYMPUS) equipped microscope. Experiments were done in triplicate, quantifying a minimum of 100 cells each time.

Flow Cytometric analysis of the Cell Cycle. Cells were cultured in 6-well plates at a confluence of 1×10^6 cells/well. Cells were treated with compounds for 24 h with respective IC_{50} values. Then, cell cycle phases and DNA content were analyzed by flow cytometry. Briefly, cells were collected and fixed with ice ethanol 70% for 2 h. Fixed cells were centrifuged (300 g, 4 °C, 5 min) and washed with cold PBS, and then stained with diamidino-2-phenylindole (DAPI, 10 μ g/mL, Triton X-100 0.1% v/v in PBS). Then, cells were filtered by a nylon mesh with a pore size of 30 μ m. Cell cycle analysis was done using a flow cytometer (Partec CyFlow space, Germany). The distribution of cells in different cell cycle phases was assessed by Partec FloMax software.

mRNA expression analysis by qPCR. Cells were cultured in 6-well plates at a confluence of 2×10^5 cells/well and kept at 37 °C in a moistened air of 5% CO_2 overnight. Then, cells were treated for 48 h with respective IC_{50} values.

For RNA extraction from cells, Trizol reagent (Cat. No: 15596-026, Invitrogen, CA, USA) was used according to the manufacturer's protocol. First-strand cDNA was generated from the cells' extracted RNA by the RevertAid First Strand cDNA Synthesis Kit, Fermentas (Cat No: #K1621, Maryland, USA) according to manufacturer's directions.

Primers (Bax, cyclin D1, VEGFA, Bcl-2, Caspase 3, c-myc, survivin and the *Homo sapiens* ribosomal protein L38 (RPL38) as a housekeeping gene) were designed using Primer Express 3.0 (PE Applied Biosystems, Foster City, CA, USA). See Table 2 for the details of primers used in quantitative real-time PCR. For accuracy and specificity, all primers were blasted in the NCBI website: <http://www.ncbi.nlm.nih.gov/tools/primer-blast/>. Primers were synthesized by the custom oligonucleotide synthesis service, Metabion (Martinsried, Germany).

Name	Formula	Structure	MW	Melting Point (°C)	Color	Yield
4a 2,6-Bis-(4-propoxy-benzylidene)-cyclohexanone (BM1)	C ₂₆ H ₂₂ O ₃		283.45	158–160.2	Yellow	78%
4b 2,6-Bis-(3-methoxy-4-propoxy-benzylidene)-cyclohexanone (BM2)	C ₂₈ H ₂₆ O ₅		442.50	162.9–164.2	Green	89%
4c 2,6-Bis-(4-allyloxy-3-methoxy-benzylidene)-cyclohexanone (BM3)	C ₂₈ H ₃₀ O ₅		446.53	182.9–184.3	Brown	85%
4d 2,6-Bis-(4-ethoxy-3-methoxy-benzylidene)-cyclohexanone (BM4)	C ₂₆ H ₃₀ O ₅		422.51	172.9–174.5	phosphorous	80%
4e 2,6-Bis-(4-hydroxy-3-methoxy-benzylidene)-cyclohexanone (BM5)	C ₂₂ H ₂₂ O ₅		366.41	145.5–147	Brown	87%

Table 1. Chemical characterization of the synthesized 2,6-bis benzylidene cyclohexanones including formula, structure, molecular weight, melting point, color and yield.

Target	Forward primer	Reverse primer	Amplicon Size (bp)
Bax	5'-GCCCTTTTGCTTCAGGGTTTC	5'-CATCCTCTGCAGTCCATGT	168
Cyclin D1	5'-GGCGGAGGAGAACAACAGA	5'-TGTGAGGCGGTAGTAGGACA	181
VEGFA	5'-TGTCTAATGCCCTGGAGCCT	5'-GCTTGTACATCTGCAAGTACG	175
Bcl-2	5'-CAGGATAACGGAGGCTGGGATG	5'-AGAAATCAAACAGAGGCCGCA	70
Caspase 3	5'-GCGGTTGTAGAAGAGTTTCGTG	5'-CTCACGGCCTGGGATTTCAA	101
c-myc	5'-CCCTCCACTCGGAAGGACTA	5'-GCTGGTGCATTTTCGGTTGT	96
Survivin	5'-TTCAAGGAGCTGGAAGGCTG	5'-AGCAATGAGGGTGGAAAGCA	151
RPL38	5'-TCACTGACAAAGAGAAGGCAGAG	5'-TCAGTGTGTCTGGTTCATTTCACTT	88

Table 2. Primers used in quantitative PCR and the amplicon sizes (bp: base pair).

Quantitative analysis was done using StepOne Real-Time PCR System (Applied Biosystems 7500, Foster City, CA, USA) with the PowerSYBR Green PCR Master Mix (Cat. No: 4309155, Applied Biosystems, Foster City, CA, USA).

Individual reaction mix contained an overall volume of 25 μ l (master mix 12.5 μ l, cDNA 3 μ l, primer 3 μ l, and H₂O 6.5 μ l). Thermocycling conditions were as follows: 50 °C for 2 minutes, 95 °C for 10 minutes, then 40 cycles of 95 °C for 30 seconds, 60 °C 30 seconds, and 72 °C for 30 seconds.

Relative quantities of target mRNA in test samples were measured and standardized to the housekeeping gene, RPL38 mRNA transcript level. The comparative Ct method was used to assess expression as previously described by Livak and Schmittgen⁸.

Statistical Analysis. IC₅₀ values were analyzed using Sigma Plot 12 software. Values for the growth inhibition study are presented as mean \pm SD, except in figures where error bars represent standard error of mean (SEM).

Analogue	24 h	48 h	72 h
Curcumin	18.43	12.33	5.42
BM1	9.85	5.45	0.72
BM2	3.95	0.72	0.56
BM3	11.71	7.53	1.39
BM4	14.15	4.35	1.96
BM5	15.22	3.72	0.83

Table 3. IC₅₀ values of synthesized 2,6-Bis Benzylidene cyclohexanone analogues in AGS cells that analyzed by MTT assay after 24 h, 48 h, and 72 h. Values are in µg/mL.




Figure 3. Inhibitory effect of synthesized compounds on AGS cells assessed with MTT assay at 24 h time point.

Results

In order to assess the effect of synthesized compounds on cell proliferation, an MTT assay was conducted to test the inhibitory effect in three time points. After 24 h, all generated analogues were cytotoxic toward gastric and esophageal cancer cells and showed lower IC₅₀ values than curcumin. As shown in Table 3 and Fig. 3, BM2 was 4.6 times more toxic than curcumin toward gastric cancer cells. Similarly, esophageal cancer cells were more susceptible to BM2 and other synthesized compounds than curcumin (Supplementary Table S1). We observed the same pattern after 48 h, with BM2 17 times more toxic than curcumin (Table 3, and Fig. 4). Similarly, 72 h post treatment, all compounds were more effective than curcumin. Three curcumin analogues revealed IC₅₀ with Nanogram/mL values (Table 3, and Fig. 5). Moreover, MTT assay on KYSE-30 cells confirmed our data and showed that synthesized compounds have cytotoxicity on esophageal cancer cells as well (Supplementary Table S1 and Fig. S1). These data revealed that all synthesized analogues showed IC₅₀ much less than curcumin in three time points.

In order to elucidate the mode of cell death, cells were stained with EB/AO, and apoptotic, necrotic, and live cells were counted. Synthetic compounds changed the morphology of treated cells to characteristic apoptotic cells. Nuclei of treated cells condensed and revealed fragmented chromatin and apoptotic bodies. As presented in Fig. 6B, treatment of AGS cells with synthesized BM2 triggered apoptotic cell death, which is characterized by fragmentation of nuclei. Quantification of treated and control cells revealed that synthesized analogues increased the number of apoptotic cells significantly compared to control cells (Fig. 6C and Fig. S2).

In order to verify that compounds trigger the apoptosis pathway, mRNA expression levels of important apoptotic factors were analyzed. Treatment with synthesized compounds elevated BAX and caspase-3 mRNA levels, and down-regulated expression of cyclin-D1, VEGFA, Bcl-2, c-myc, and Survivin (Fig. 7 and Fig. S3).

In order to further confirm anti-proliferative effects, cell cycle distribution of the treated cells was evaluated. As displayed in Fig. 6, synthesized compounds were more potent than curcumin at arresting the cell cycle at G1 phase. BM2 and BM3 were most effective at increasing the cell population at G1 phase. Simultaneously, analogues decreased the number of cells at S phase (Fig. 8 and Fig. S4).




Figure 4. Inhibitory effect of synthesized compounds on AGS cells assessed with MTT assay after 48 h time point.




Figure 5. Inhibitory effect of synthesized analogues on AGS cells determined by MTT assay after 72 h time point.

Discussion

To date over 100 different clinical trials have been completed with curcumin which clearly shows its safety, tolerability, and effect against numerous chronic diseases in humans³.

Curcumin, a polyphenolic natural product, shows therapeutic function against a variety of diseases. These activities are attributed mainly to its chemical structure and unique physical, chemical, and biological properties. It is a di-feruloyl methane molecule [1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] containing two ferulic acid residues linked by a methylene connection. It has three key functional groups: an aromatic *o*-methoxy phenolic group, α , β -unsaturated β -diketo moiety and a seven carbon linker⁹. In this study we designed different analogues of curcumin with non-polar and hydrophobic groups (methoxy, propoxy, ethoxy, and allyloxy), in order to test the effect of less polar synthesized analogues on cancer cell proliferation and compare them with the anti-cancer effect of curcumin.




Figure 6. EB/AO staining for detecting apoptotic cells. (A) Control un-treated AGS cells. (B) Representative micrograph of apoptotic cells treated with BM2 that are characterized with fragmented and condensed nuclei of cells. (C) Quantification of the cells with normal, necrotic and apoptotic representation.




Figure 7. Relative expression levels of Bax, cyclin D1, VEGFA, Bcl-2, Caspase 3, c-myc, survivin and RPL38 mRNA in AGS cells. All Ct values were normalized with the *homo sapiens* ribosomal protein L38 (RPL38) as a housekeeping gene.




Figure 8. Flow cytometric analysis of the cell cycle. Curcumin analogues altered distribution of the AGS cells in cell cycle phases, which indicates that cell cycle arrested at G1 phase.

Recently, it has been reported that replacement of two OH groups in curcumin with less polar groups like methoxy (OCH₃) increases the anti-proliferative activity of arene-ruthenium(II) curcuminoid complexes in tumor cells. This report states that improved anti-cancer function is associated with apoptotic activity¹⁰. These findings are in accordance with our results: by decreasing curcumin polarity, its *in vitro* anti-tumor activity increases significantly. Our various experimental results on esophageal and gastric cancer cells revealed that all synthesized analogues of curcumin are more toxic than curcumin: after 48 h treatment in gastric cancer cells, BM2 was 17 times more toxic than curcumin (Fig. 4).

Very recently it is reported that curcumin triggered cell cycle arrest at G1 phase, and reduced the cell population in S phase in p53-mutated human colon adenocarcinoma cells¹¹. These findings are in agreement with our data, which demonstrate that synthesized analogues increase cell population at G1 phase and decrease cell population at S phase (Fig. 8).

The same study reports that curcumin induced apoptosis in p53-mutated COLO 320DM colon adenocarcinoma cells¹¹. Our novel synthesized compounds were more effective than curcumin at triggering apoptosis (Figs 6 and 7 and Supplementary Figs S2–S4).

It has been reported that curcumin induced apoptosis in leukemia cells by PARP-1 cleavage, increased level of caspase-3, apoptosis inducing factor (AIF) and down-regulation of Bcl2¹². Another study suggested that dendrosomal curcumin (DNC) significantly increased cell population in SubG1, induced apoptosis and up-regulated p21, BAX, and Noxa in hepatocarcinoma cell lines. While the expression of Bcl-2 decreased¹³. Moreover, it has been reported that a curcumin analogue ((1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione) down-regulated cyclin D1 and activated Caspase 3, 8 and 9 in lung adenocarcinoma (A549), leukemia (K562) and colon cancer (SW480) cells¹⁴. Another study showed that curcumin suppressed VEGF secretion from tumor cells both *in vitro* and *in vivo*, and subsequently could block VEGF-VEGFR2 signaling pathways¹⁵. It has been evidenced that curcumin combination with resveratrol synergistically induced apoptosis in cigarette smoke condensate transformed breast epithelial cells by increasing Bax/Bcl-xL ratio, Cytochrome C release, cleaved product of PARP and caspase 3. Whereas, this combination decreased c-myc and cyclin-D1¹⁶. Nevertheless, it has been demonstrated that dimethoxy curcumin (DMC) as a non-polar and lipophilic analogue of curcumin down-regulating survivin and upregulating E-cadherin in colon cancer cells which significantly suppressed the growth and migration of cells¹⁷.

Our novel synthesized compounds potentially up-regulated Bax and caspase-3 and down-regulated anti-apoptotic players (Fig. 7).

Cyclin D1 is one of the G1 phase related regulatory factors¹⁸; its down-regulation in our results verifies potential effect of novel analogues on cell cycle arrest at G1 phase (Fig. 8).

Taken together, novel synthetic 2,6-bis benzylidene cyclohexanone analogues were more efficient than curcumin to inhibit cancer cell proliferation, trigger apoptosis, and arrest cell cycle at G1 phase. These data suggest that cyclohexanone analogues of curcumin could be promising anti-cancer agents to consider for more research on animal tumor models and even human clinical trials.

References

1. Aggarwal, B. B., Gupta, S. C. & Sung, B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. *British journal of pharmacology* **169**, 1672–1692 (2013).
2. Aggarwal, B. B., Deb, L. & Prasad, S. Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses. *Molecules* **20**, 185–205 (2014).
3. Kunnumakkara, A. B. *et al.* Curcumin, The Golden Nutraceutical: Multitargeting for Multiple Chronic Diseases. *British Journal of Pharmacology* (2016).

4. Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B. & Aggarwal, B. B. Curcumin and cancer: an “old-age” disease with an “age-old” solution. *Cancer letters* **267**, 133–164 (2008).
5. Kocaadam, B. & Şanlıer, N. Curcumin, an active component of turmeric (*Curcuma longa*), and its effects on health. *Critical reviews in food science and nutrition*, 00–00 (2015).
6. Modzelewska, A. *et al.* Anticancer activities of novel chalcone and bis-chalcone derivatives. *Bioorganic & medicinal chemistry* **14**, 3491–3495 (2006).
7. Ribble, D., Goldstein, N. B., Norris, D. A. & Shellman, Y. G. A simple technique for quantifying apoptosis in 96-well plates. *BMC biotechnology* **5**, 12 (2005).
8. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2[−]ΔΔCT method. *methods* **25**, 402–408 (2001).
9. Indira Priyadarsini, K. Chemical and structural features influencing the biological activity of curcumin. *Current pharmaceutical design* **19**, 2093–2100 (2013).
10. Caruso, F. *et al.* The *in vitro* antitumor activity of arene-ruthenium (II) curcuminoid complexes improves when decreasing curcumin polarity. *Journal of Inorganic Biochemistry* (2016).
11. Dasiram, J. D., Ganesan, R., Kannan, J., Kotteeswaran, V. & Sivalingham, N. Curcumin inhibits growth potential by G1 cell cycle arrest and induces apoptosis in p53-mutated COLO 320DM human colon adenocarcinoma cells. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* **86**, 373–380, doi:10.1016/j.biopha.2016.12.034 (2016).
12. Mishra, D., Singh, S. & Narayan, G. Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage. *Asian Pacific Journal of Cancer Prevention* **17**, 3865–3869 (2016).
13. Montazeri, M. *et al.* Dendrosomal Curcumin Nanoformulation Modulate Apoptosis-Related Genes and Protein Expression in Hepatocarcinoma Cell Lines. *International journal of pharmaceutics* (2016).
14. Sufi, S. A. *et al.* In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione. *Biomedicine & Pharmacotherapy* (2016).
15. Fu, Z. *et al.* Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway. *Oncotarget* **6**, 19469 (2015).
16. Mohapatra, P. *et al.* Resveratrol and curcumin synergistically induces apoptosis in cigarette smoke condensate transformed breast epithelial cells through a p21 Waf1/Cip1 mediated inhibition of Hh-Gli signaling. *The international journal of biochemistry & cell biology* **66**, 75–84 (2015).
17. Chen, D. *et al.* Dimethoxy Curcumin Induces Apoptosis by Suppressing Survivin and Inhibits Invasion by Enhancing E-Cadherin in Colon Cancer Cells. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research* **22**, 3215 (2016).
18. Sha, J. *et al.* Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling. *Biomedicine & Pharmacotherapy* **84**, 177–184 (2016).

Acknowledgements

This study was supported by a thesis grant for MD students from the Ardabil University of Medical Sciences. The authors thank Kenton Sena for critical reading and revising of the manuscript.

Author Contributions

F.A. performed experiments, analyzed data, and wrote the paper; M.K. synthesized and verified compounds; H.P.D. consulted the project, and N.J. designed experiments, interpreted results and wrote the paper.

Additional Information

Supplementary information accompanies this paper at doi:10.1038/s41598-017-02666-4

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017